The U.S. uranium enrichment buildout is entering a more urgent phase as federal officials press developers to move faster ahead of a critical 2028 deadline. The most immediate issue is straightforward: waivers that have allowed some continued imports of Russian enriched uranium are set to expire at the start of 2028, and federal officials have indicated they do not plan to extend them.
That timing is forcing the market to focus on one question: whether new U.S.-linked enrichment capacity can be online quickly enough to support both the existing reactor fleet and next-generation nuclear projects. Three companies sit near the center of that answer: Centrus Energy, Orano and General Matter.
The pressure reflects more than supply-chain caution. It also highlights the broader challenge facing a U.S. nuclear expansion strategy that depends on reliable access to enriched uranium, including high-assay low-enriched uranium, or HALEU, for advanced reactors expected later this decade.
Key Facts
- The U.S. Department of Energy has awarded roughly $900 million each to Centrus Energy, General Matter and Orano to support domestic enrichment-related expansion.
- Waivers that have allowed certain Russian enriched uranium imports are scheduled to expire at the start of 2028.
- Centrus has indicated an initial HALEU output target of 12 metric tons annually, with full-rate scaling expected after 2030.
- General Matter has been described as offering a plan targeting 355 metric tons of HALEU annually for the same $900 million support package.
- Both Centrus and General Matter have signaled first new capacity ambitions around 2029, while Orano is advancing a Tennessee project aimed at replacing Russian-linked supply.
Uranium Enrichment Buildout
The current push to expand uranium enrichment capacity stems from a strategic vulnerability exposed after Russia’s invasion of Ukraine in 2022. Prices rose across the nuclear fuel chain, and the U.S. moved to restrict Russian enriched uranium imports. Although temporary waivers helped avoid immediate disruptions for U.S. utilities, those measures also delayed the need for a hard market reset. With the 2028 cutoff now in view, that cushion is shrinking.
For investors, the key issue is not simply whether money has been committed, but whether funded projects can convert capital into commercial output on schedule. Federal support has been substantial, yet enrichment remains one of the most technically demanding segments of the nuclear supply chain. Licensing, centrifuge manufacturing, cascade deployment, feedstock access and customer qualification all influence whether announced capacity becomes usable fuel in time.
The companies involved have very different profiles. Centrus is the most established U.S.-linked name and already holds the distinction of operating the only U.S. Nuclear Regulatory Commission-licensed facility producing HALEU-level uranium. Orano brings decades of enrichment experience from Europe and a deeper operational base, though it is foreign-backed. General Matter is the least proven publicly, but it has attracted attention because of its ambitious scale targets and startup-style approach under leadership linked to aerospace engineering and venture capital.
Washington can fund enrichment plants, but the market still needs real tons of fuel before 2028 turns a policy deadline into a supply problem.
Why the capacity gap matters
The U.S. commercial reactor fleet still needs steady enriched uranium supplies, but the bigger long-term bottleneck may be HALEU, the higher-enriched fuel required by many advanced reactor designs. If domestic HALEU production remains limited, reactor developers could face delays even if plant construction and licensing move forward. That makes enrichment a gating factor for any broader nuclear renaissance.
Centrus has tried to strengthen its position through supply agreements with advanced reactor developers including Radiant, X-energy and Antares. General Matter has also been linked to contracts with X-energy, Antares and an unnamed utility. Those commercial ties suggest customer demand is forming, but they also raise the stakes: capacity promises now need to align with actual delivery volumes by the end of the decade.
Implications for Investors
The most immediate takeaway for investors is that uranium enrichment is shifting from a niche policy issue to a measurable execution story. Public funding has reduced some financing risk, but project timing now matters more than headline award sizes. Companies able to demonstrate licensed production, manufactured centrifuges, construction milestones and signed offtake commitments may command a premium as the 2028 deadline approaches.
Centrus Energy is likely to remain under particular scrutiny. Its early-mover advantage in licensed HALEU production gives it strategic relevance, especially for investors looking at the domestic nuclear supply chain. But the market may also compare its more modest initial volume targets with the far larger ambitions attributed to General Matter. If Centrus cannot accelerate timelines or expand planned output, some investors may question whether its current leadership can translate into dominant scale.
Orano presents a different kind of exposure. Its industrial experience could make it a credible beneficiary of U.S. localization efforts, but its foreign ownership may limit the degree of strategic preference it receives relative to American-controlled platforms. General Matter, meanwhile, offers the highest upside if its capacity claims prove achievable, but also the greatest execution risk because its technology, construction progress and commercial readiness remain less visible.
Beyond individual names, the enrichment push has implications across the nuclear ecosystem. Utilities, reactor developers, uranium producers, conversion providers and specialized manufacturers all stand to benefit if domestic fuel assurance improves. The risk is that delays in enrichment capacity could ripple across the rest of the supply chain, constraining reactor fuel availability even as demand for nuclear generation strengthens.
The next phase of this story will be defined by milestones rather than announcements: licensing progress, construction updates, centrifuge deployment rates and binding delivery schedules. If new enrichment capacity arrives on time, it could reshape the U.S. nuclear fuel market; if it slips, the 2028 deadline may become a pivotal stress test for the sector.